A multiple myeloma candidate with a new mode of action is now in Phase 2 patient trials following positive Phase 1 results showing it kills cancer cells without toxicity to patients.
With Rare Disease Day coming up next weekend, we at BIA are taking time to reflect on our important advocacy and thought leadership in this space, but also on what we hope to achieve in terms of boosting our influence collectively alongside our Charity Partner of the Year.
22,000 sq ft of space in Wilton Centre’s Technical Development Area (TDA) has been leased to growing companies breathing new life into used metals and accelerating Teesside’s net zero ambitions.
In this blog, Katherine Powers, Life Sciences Senior Analyst at RSM US, and Max Stanyard, Life Sciences Senior Analyst at RSM UK, highlight the investment uncertainty in the UK-US life sciences ecosystem.
The UK’s life sciences and biotech sector has long been recognised for its scientific excellence, vibrant innovation and dynamic startup culture around the globe. In the past year, interest in our business ecosystem from international partners has markedly accelerated.
The BIA has submitted its response to the HM Treasury's Business Rates and Investment: Call for Evidence, which sought to understand the impact of business rates on investment.
In this blog, Richard Turner, Senior Managing Director at FTI Consulting, discusses how licence and collaboration agreements in life sciences can create significant tax consequences.
Cancer Research Horizons adds the Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) study dataset to its growing portfolio of commercially licensable data assets.
It’s been an energising week across the UK life sciences landscape, marked by major investment, important conversations and new opportunities for our community.
Harness Therapeutics nominates HRN001 as its lead drug candidate for Huntington's disease and the formation of a clinical advisory board to support advancement towards clinical evaluation.
In this guest blog, Hareklea Markides, Innovation Lead - Medicines Manufacturing at Innovate UK, reflects on the UK BioIndustry Association's (BIA) annual #bioProcessUK conference.
TechBio’s potential to both transform our sector and provide precision diagnosis and care to patients is well recognised, and TechBio Boost is playing a vital role in scaling companies in this space.
Coulter Partners successfully led a search assignment for Concept Life Sciences and is pleased to announce the placement of Dr. Adam Davenport as Chief Scientific Officer (CSO).
This webinar showcased how the 3Rs were being turned into real action across modern research. Watch to hear insights from leading UK experts and industry innovators on policy shifts, future funding, and cutting-edge approaches improving both science and animal welfare.
